Report Overview

The China Cystic Fibrosis Therapeutics market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The diagnosis and treatment of Cystic Fibrosis disease are an important public health issue and a challenge for medical care in China. The Incidence rate of Cystic Fibrosis disease in China is 1 person per 1,00,000. With its enormous population, increase in paediatric population (14.65 million in 2019) and economic inequalities, several mutations (1898+5G>T, c.2909G>A, 3068T>G) in cystic fibrosis disease in China faces considerable challenges in improving the standard of care for patients who are affected by cystic fibrosis disease. It is found that the median age of a patient who is affected by cystic fibrosis is 10.55 years old.



Market Drivers

China is the growing market for Cystic Fibrosis disease due to increasing paediatric population (14.65 million in 2019), increase in mutation of genes, rise in smoking rates (300 million smokers in 2019 and 180 million children are exposed to second-hand smoke at least once a day in typical week) results in increase in Prevalence rate. Advances in screening and treatment technologies will lead to increase in market growth of cystic fibrosis disease. The growing focus of companies towards product enhancement and clinical studies will foster the growth of the market.

There are some restraining factors for the growth of Cystic Fibrosis therapeutics market in China such as complex drug development process, expensive treatment options, under diagnosis, misdiagnosis and missed diagnosis.